How Did This Low-Growth Stock Sneak Into IBD Growth Screens?Investors Business Daily · 5 days ago
Meta's $1,000 Bull Case: How Muse AI Changes The Valuation Game | IBDInvestors Business Daily · 6 days ago
SKYRIZI® (risankizumab) and RINVOQ® (upadacitinib) Data Highlight Long-Term Clinical and Endoscopic Outcomes Across Inflammatory Bowel Disease (IBD) at UEGW 2026GuruFocus · Oct 17, 2026
SKYRIZI® (risankizumab) and RINVOQ® (upadacitinib) Data Highlight Long-Term Clinical and Endoscopic Outcomes Across Inflammatory Bowel Disease (IBD) at UEGW 2026PRNewsWire · Oct 17, 2026
Is Inspire Corporate Bond ETF (IBD) a Strong ETF Right Now?Zacks Investment Research · Oct 14, 2026
Celltrion to Present New Analyses of ZYMFENTRA® (infliximab-dyyb) in Crohn's Disease and Ulcerative Colitis at ACG 2026GuruFocus · Oct 11, 2026The Inspire Corporate Bond ETF primarily invests in high-quality debt securities issued by large American corporations that are selected for their inspiring and biblically aligned principles. This fund aims to mirror the performance outcomes of the Inspire Corporate Bond Index.